Industrial Automation for Pharmaceutical & Life Sciences

Industrial Automation for Pharmaceutical & Life Sciences

Industrial automation for pharmaceutical and life sciences facilities is not “standard process automation with stricter documentation.” It is a regulated engineering discipline where scope, design, implementation, testing, and handover must support product quality, data integrity, patient safety, and operational continuity. Typical projects include sterile manufacturing, oral solid dose, biotech upstream/downstream, utilities, clean utilities, packaging, warehouse automation, and laboratory support systems. The engineering challenge is to deliver a system that is technically robust, compliant, and easy to validate.

How the service is typically scoped

A pharmaceutical automation scope usually begins with a user requirements basis and a risk-based assessment of what must be controlled, recorded, and defended during inspection. For regulated systems, the project often includes process control, batch orchestration, recipe management, alarms, historian, electronic records, integration to MES/ERP, and cybersecurity controls. The scope should be defined around the intended use, critical quality attributes, and critical process parameters rather than only around equipment count.

Common deliverables include:

• URS, functional specification, and control philosophy
• Process narratives and cause-and-effect matrices
• I/O list, instrument index, and network architecture
• PLC, HMI, SCADA, batch, and historian configuration
• Alarm rationalization and audit trail design
• Validation documentation: FAT, SAT, IQ/OQ support, traceability matrix
• Cybersecurity and access control concept
• As-built documentation, backup images, and lifecycle support plan

Where batch manufacturing is involved, ISA-88 is often the backbone for scope definition and software structure. The physical model, procedural model, and recipe hierarchy help separate equipment design from product-specific logic. ISA-88.01 is particularly useful when aligning the automation scope with modular equipment and repeatable validation packages.

Standards and compliance drivers

For life sciences, the automation stack must satisfy both technical standards and regulatory expectations. In Europe, the machinery and control system must align with the EU Machinery Directive 2006/42/EC or the Machinery Regulation transition path where applicable, while electrical assemblies typically follow EN/IEC 60204-1 for machinery electrical equipment. For control panels, IEC 61439 is often relevant for low-voltage switchgear and controlgear assemblies, especially where the panel builder is responsible for design verification and routine verification.

For software and data integrity, the most cited expectations come from GAMP 5 principles, FDA 21 CFR Part 11 in U.S.-facing projects, and EU GMP Annex 11 for computerized systems. Annex 11 requires risk management, validation, data integrity, periodic review, and supplier assessment. Audit trails, access control, and record retention are not optional features; they are part of the compliance architecture.

Where functional safety is involved, IEC 61511 is the key reference for process sector safety instrumented systems. If packaging or discrete machinery safety functions are included, ISO 13849-1 or IEC 62061 may be more applicable depending on architecture and risk reduction method. For industrial cybersecurity, IEC 62443 is increasingly expected, and in Europe NIS2-driven governance is pushing operators to formalize asset inventory, access management, patching, logging, and incident response.

Typical engineering decisions

One of the first decisions is whether the facility needs a PLC-centric architecture, a DCS, or a hybrid. In pharmaceutical manufacturing, PLC/SCADA is common for utilities, packaging, and skid systems, while DCS or batch platforms may be preferred for larger process plants. The choice depends on batch complexity, operator workflow, integration needs, and validation burden.

Another key decision is where to place intelligence. For example, should a skid have autonomous local control with a higher-level supervisory layer, or should all sequencing reside in the central system? Local autonomy can improve resilience and commissioning speed, but centralization may simplify recipe management and audit control. The right answer depends on the criticality of the process and the desired maintenance model.

Data architecture is also a major design topic. In regulated environments, time synchronization, user authentication, electronic signatures, and event logging must be designed from the start. If historians are used, the system should preserve context: who changed what, when, why, and under which approved change control. This is essential for data integrity expectations under Annex 11 and Part 11.

Decision area	Common option A	Common option B	Typical selection driver
Batch control	ISA-88 batch engine	Custom sequence logic	Validation efficiency, recipe reuse, auditability
Control platform	PLC + SCADA	DCS	Plant scale, integration complexity, operator model
Safety	IEC 61511 SIS	Machine safety PLC	Process hazard vs machinery hazard
Cybersecurity	IEC 62443 zoning/conduits	Basic IT controls only	Regulatory exposure, remote access, plant criticality

Validation and delivery approach

Delivery in this sector is rarely linear. It is usually V-model based, with early requirement definition, design reviews, code/configuration development, staged testing, and controlled release. The validation strategy should be risk-based and traceable. A good traceability matrix links user requirements to design elements, test cases, and final acceptance evidence.

FAT and SAT are not merely functional demonstrations; they are evidence-generating activities. FAT should verify logic, alarms, interlocks, recipe handling, data capture, and simulated failure modes before site installation. SAT confirms field wiring, device integration, network behavior, and real equipment response. IQ/OQ then demonstrate that the installed system is correct and operates as intended under defined conditions.

For panel and electrical design, practical compliance details matter. EN/IEC 60204-1 clauses addressing emergency stop functions, control circuits, and protective bonding are frequently reviewed during audits. If the project includes low-voltage assemblies, IEC 61439 design verification covers temperature rise, dielectric properties, short-circuit withstand, and clearances/creepage. These are not paperwork exercises; they affect reliability and inspection readiness.

Alarm management is another area where pharmaceutical projects often succeed or fail. Over-alarming creates operator fatigue and weakens response to genuine deviations. A rationalized alarm set, aligned to operational intent and criticality, improves both compliance and usability. Many teams adopt ISA-18.2 principles even when not formally mandated, because they support better lifecycle control.

What good looks like in practice

A well-executed pharmaceutical automation project produces a system that is understandable, maintainable, and inspectable. Operators should be able to run the process consistently. Quality teams should be able to reconstruct events. Maintenance should be able to isolate faults without breaking validated state. Engineering should be able to change the system under formal change control without losing traceability.

In short, the best projects are not the most complex; they are the ones where scope, standards, and validation are aligned from day one. If you are planning a new plant, a utility upgrade, a packaging line, or a regulated SCADA modernization, it pays to define the compliance model and engineering architecture early so the project can be delivered once, validated once, and maintained confidently for years to come — discuss your project via /contact.